When is genetic testing indicated for diabetes mellitus and which genes should be included in the testing panel?

Genetic Testing for Diabetes Mellitus

Genetic testing is mandatory for all infants diagnosed with diabetes before 6 months of age and should be performed in individuals with atypical diabetes and a strong family history suggestive of monogenic diabetes (MODY), particularly when multiple family members have diabetes not characteristic of type 1 or type 2 diabetes. 1

When to Order Genetic Testing

Neonatal Diabetes (Age <6 months)

• Test all infants diagnosed before 6 months of age - this is non-negotiable 1, 2
• Critical because 30-50% of KATP-related neonatal diabetes patients can switch from insulin to high-dose oral sulfonylureas with improved glucose control 1
• Seven different genes can cause transient or permanent neonatal diabetes 2

MODY (Maturity-Onset Diabetes of the Young)

Test when patients meet these criteria:

• Atypical diabetes presentation with multiple affected family members across generations 1
• Diabetes not fitting type 1 or type 2 patterns 1
• MODY clinical risk calculator >25% post-test probability in patients not requiring insulin within 6 months of diagnosis 3
• Consider testing even if diabetes autoantibodies are present (GAD, IA-2A, ZnT8) - their presence doesn't completely exclude monogenic diabetes, though it makes it less likely 1, 3

Additional Helpful Criteria

• 2-hour postprandial urinary C-peptide to creatinine ratio ≥0.2 nmol/mmol helps distinguish HNF1A- or HNF4A-MODY from type 1 diabetes 3
• Three or more negative antibodies with clinical features suggestive of MODY 3

Which Genes to Test

Neonatal Diabetes Panel

Include these genes 1, 2:

• KCNJ11 (Kir6.2) - sulfonylurea-responsive
• ABCC8 - sulfonylurea-responsive
• INS (insulin gene) - second most common cause, requires insulin therapy
• GCK (glucokinase)
• PDX1
• PTF1A
• GATA6
• EIF2AK3 (Wolcott-Rallison syndrome)
• EIF2B1
• FOXP3 (IPEX syndrome)

MODY Panel

Prioritize the three most common forms 1:

• GCK (glucokinase-MODY) - mild, stable hyperglycemia, typically no treatment needed
• HNF1A - progressive, sulfonylurea-responsive
• HNF4A - progressive, sulfonylurea-responsive

These three account for the majority of MODY cases and have the most significant treatment implications 1, 4

Testing Methodology

• Next-generation sequencing (NGS) multigene panels are now standard and increasingly cost-effective 1, 2, 5, 6
• Allows simultaneous assessment of multiple genes
• More efficient than sequential single-gene testing

Critical Treatment Implications

Why This Matters

The genetic diagnosis directly changes management:

GCK-MODY: No pharmacologic therapy needed - stable mild hyperglycemia without progression 1

HNF1A-MODY and HNF4A-MODY: Sulfonylureas as first-line therapy (not insulin or metformin) 1

KATP mutations (KCNJ11, ABCC8): High-dose sulfonylureas instead of insulin 1, 2

INS mutations: Insulin therapy required 1

Important Caveats

Do NOT routinely test:

• Type 2 diabetes patients - no role for routine genetic testing; confine to research settings 2
• Polygenic risk scores for type 2 diabetes have limited clinical utility despite identifying 30+ genetic factors 2

Pitfalls to Avoid:

• Reduced penetrance is increasingly recognized - some individuals carry pathogenic variants but don't develop diabetes 7
• Polygenic risk may influence penetrance 7
• Phenotype may not always correlate with genotype due to environmental factors 2
• Consult a center specializing in diabetes genetics for variant interpretation and genetic counseling 1

Essential Follow-up:

• Genetic counseling is mandatory to explain inheritance patterns, ensure correct diagnosis understanding, and address cardiovascular risk 1
• Test family members once a pathogenic variant is identified
• Implications extend beyond the proband to multiple family members 3